The shares of clinical-stage biopharmaceutical company 89bio Inc. ETNB, +4.55% rose 4.8% in premarket trading on Tuesday after Evercore ISI analysts began coverage of the stock. The company’s focus is on developing pegozafermin, a treatment that can be used to treat liver and cardio-metabolic diseases. This includes non-alcoholic steatohepatitis or inflammation due to fat buildup in the liver. Investors have remained cautious about NASH treatments because of the popularity of incretin mimics, like Novo Nordisk NVO, -0.03%Wegovy for obesity. Evercore analysts Liisa bayko and Seema sheoran said in a report on Tuesday that based upon emerging evidence “we believe advanced NASH requires specialized medicine” to reverse the disease’s course.